期刊文献+

非小细胞肺癌患者血清中MALAT1表达水平及其临床意义 被引量:13

Expression of MALAT1 in serum of the patients with non-small cell lung cancer(NSCLC) and its clinical significance
下载PDF
导出
摘要 目的探讨肺腺癌转移相关转录因子1(MALAT1)在非小细胞肺癌(NSCLC)患者血清中的表达水平及其诊断价值。方法提取60例NSCLC患者、42例肺良性病变患者及50例健康人血清中的总RNA,用Taq Man实时荧光定量RT-PCR检测MALAT1基因的表达水平并分析其与NSCLC患者临床病理因素的关系,以受试者工作特征曲线(ROC)分析血清MALAT1的诊断效能。结果肺癌组血清MALAT1相对表达水平(0.51±0.09)低于肺良性病变组(0.80±0.12)及健康人对照组(1.01±0.30),差异有统计学意义(q分别为13.95、12.27,P<0.01);肺良性病变组血清MALAT1表达水平低于健康人对照组(q=10.24,P<0.01);腺癌患者血清MALAT1相对表达量(0.57±0.04)较鳞癌患者(0.45±0.07)明显增高(t=4.260,P<0.01),而与TNM分期、淋巴结转移和肿瘤分布部位无显著相关性(P>0.05);ROC曲线下面积(AUCROC)为0.956,当cut off值为0.62时,敏感性和特异性分别是87.5%和94.1%,诊断指数为181.6%。结论血清MALAT1检测效能好,可用于NSCLC的诊断及病理类型的鉴别。 Objective To investigate the expression level of metastasis associated lung adenocarcinoma transcript 1( MALAT1) in serum of the patients with non-small cell lung cancer( NSCLC) and its diagnostic value. Methods The total RNAs were extracted from serum samples of 60 patients with NSCLC,42 patients with benign lung lesions and 50 healthy controls,respectively. Then,the expression level of serum MALAT1 was detected by real-time PCR,and its correlation with clinical pathological parameters was analyzed.The diagnostic efficacy of serum MALAT1 was analyzed by the receiver operating characteristic( ROC) curve. Results The relative expression level of MALAT1 in the patients with NSCLC( 0. 51 ± 0. 09) was significantly lower than those in the patients with benign lung lesions( 0. 80 ± 0. 12,q = 13. 95,P〈0. 01) and healthy controls( 1. 01 ± 0. 30,q = 12. 27,P〈0. 01). The expression level of MALAT1 in the patients with benign lung lesions was significantly lower than that in healthy controls( q = 10. 24,P〈0. 01). The relative expression level of serum MALAT1 in adenocarcinoma patients( 0. 57 ± 0. 04) was significantly higher than that in squamous carcinoma patients( 0. 45 ± 0. 07,t = 4. 260,P〈0. 01). However,the expression level of serum MALAT1 was not correlated with TNM stage,lymphatic metastasis and tumor location( P〉0. 05). The area under the curve( AUC^ROC) was 0. 956. When the cutoff value of serum MALAT1 level was set as 0. 62,the sensitivity and specificity were 87. 5% and 94. 1%,respectively,and the diagnostic index was 181. 6% for the diagnosis of NSCLC. Conclusion The detection of serum MALAT1 level may be helpful for the diagnosis of NSCLC and the differentiation of pathologic types of NSCLC.
出处 《临床检验杂志》 CAS CSCD 2016年第2期114-117,共4页 Chinese Journal of Clinical Laboratory Science
基金 湖南省科技计划(15C0145)
关键词 肺腺癌转移相关转录因子1 非小细胞肺癌 血清学生物标志物 诊断 metastasis associated lung adenocarcinoma transcript 1 non-small cell lung cancer serum biomarker diagnosis
  • 相关文献

参考文献11

  • 1Gutschner T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer ceils [ J ]. Cancer Res, 2013, 73 (3) : 1180-1189.
  • 2Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer [J]. Transl Res, 2015, 165(1):74-90.
  • 3徐静,周洪兴.血清正五聚蛋白3和人附睾蛋白4联合检测在非小细胞肺癌辅助诊断及预后评估的价值[J].临床检验杂志,2015,33(4):282-284. 被引量:8
  • 4Gutschner T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells[J]. Cancer Res, 2013, 73(3) : 1180-1189.
  • 5Tano K, Mizuno R, Okada T, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility- related genes[J]. FEBS Lett, 2010, 584(22) :4575-4580.
  • 6Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth[ J]. J Thorac Oncol, 2011, 6(12) :1984-1992.
  • 7Shen L, Chen L, Wang Y, et al. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transi- ton in lung cancer[ J]. J Neurooncol, 2015, 121 (1) :101-108.
  • 8Fengjie G, Feng Y, Jing W, et al. Expression of MALAT1 in the pe- ripheral whole blood of patients with lung cancer[ J]. Biomed Rep, 2015,3(3) :309-312.
  • 9佟威威,佟广辉,王婧,秦晓松,卢丽萍,刘勇.Cyfra21-1、NSE、SCCA和CRP在肺癌诊断中的应用[J].中国免疫学杂志,2015,31(3):396-400. 被引量:64
  • 10Daniel GW, Georg J, Swaantje C, et al. Evaluation of long noncod- ing RNA MALAT1 as a candidate blood-based biomarker for the di- agnosis of non-small cell lung cancer[ J ]. B MC Res Notes ,2013,6: 518-526.

二级参考文献18

  • 1程玉萍,华川.C反应蛋白测定在肿瘤中的临床应用[J].华北国防医药,2005,17(3):202-203. 被引量:28
  • 2郝敏,王静芳.宫颈癌流行病学研究与调查[J].国外医学(妇幼保健分册),2005,16(6):404-406. 被引量:91
  • 3Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the cross- roads between innate immunity, inflammation, matrix deposition, and female fertility[J]. Annu Rev Immunol, 2005, 23:337-336.
  • 4Zhang D, Ren WH, Gao Y, et al. Clinical significance and prognos- tic value of pentraxin-3 as serologic biomarker for lung cancer[J]. A- sian Pac J Cancer Prev, 2013,14(7) :4215-4221.
  • 5Jiang Y, Wang C, Lv B, et al. Expression level of serum human epi- didymis 4 and its prognostic significance in human non-small cell lung cancer[J]. Int J Clin Exp Med, 2014,7 (12) :5568-5572.
  • 6Nagy B Jr, Bhattoa HP, Steiber Z, et al. Serum human epididymis protein 4 ( HE4 ) as a tumor marker in men with lung cancer[J]. Clin Chem Lab Med, 2014,52 ( 11 ) : 1639-1648.
  • 7Stallone G, Cormio L, Netti GS, et al. Pentraxin 3 : a novel biomark- er for predicting progression from prostatic inflammation to prostate cancer[J]. Cancer Res, 2014,74(16) :4230-4238.
  • 8Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnositic and prognostic marker for lung cancer [J]. Tumour Biol, 2012,33 (4) :1141-1149.
  • 9孙淑娟,宋印利.CEA、NSE、CYFRA21-1联合检测肺癌的临床意义[J].肿瘤学杂志,2008,14(4):317-319. 被引量:7
  • 10王俊雄,姜春燕,李敏,朱圣韬,张澍田.食管鳞癌细胞中五聚素3基因的表达及甲基化[J].中华临床医师杂志(电子版),2012,6(24):8114-8117. 被引量:3

共引文献70

同被引文献87

引证文献13

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部